Array Biopharma Inc. (NASDAQ:ARRY) Trading Up Ahead of Earnings Call, JetBlue Airways Corporation (NASDAQ:JBLU) Also Scheduled to Announce Earnings
Northern, WI 04/23/2013 (GDPInsider) – Array Biopharma Inc. (NASDAQ:ARRY) is trading up ahead of its scheduled April 29 earnings call. The stock opened at $5.99 and is currently trading up 4.19%. The healthcare and biopharmaceutical company focuses on the discovery, development and commercialization of drugs aimed at treating patients who suffer from inflammatory and cancer-related illnesses. The company has been trading for 12 years publicly and in that time has developed a strong series of early-stage drug candidates. Presently there are several drug candidates in the pipeline including AMG 151, ARRY-380, MEK162 and ARRY-614.
Analysts point to the company’s stock of drug candidates as strong underpinnings for growth. The company’s MEK programs in particular are key for investors and the development of the drug Selumetinib is entering a Phase III study in small cell lung cancer. Analysts have set a target price for the stock at $6.17 and the stock is currently trading 41.39% above its 50-day moving average. Analysts expect EPS this year to rise by 67.13% and the stock is currently trading 3.24% above its 52-week high.
These underlying numbers along with the strong internal developments of Array’s drug candidates is cited as key components feeding into the value of the stock.
Is ARRY a solid investment at these levels? Get exclusive data and trends here.
JetBlue Airways Corporation (NASDAQ:JBLU) is currently trading up 1.27% having opened at $7.06. The company is scheduled to release its Q1 earnings report on Thursday April 25, 2013 and Wall Street is predicting no change in earnings from Q1 2012. The expectation is that earnings of 9 cents a share will be supported by expected Q1 revenues of $1.29 billion. The total expected revenues for JetBlue is expected to be $5.45 billion and analysts point to the strong performance of the company in the last four quarters prior.
Not much is predicted in terms of movement and several analysts have rated the stock as “hold.” The target price for the stock is set at $7.70 and the current trading price is 9.85% above its 50-day moving average. JetBlue has a forward P/E of 9.67 and the market cap is currently $1.99 billion. The technical chart for JetBlue has been sloping upwards for the last six months and EPS this year is expected to rise by 31.50%.
How Should Investors Trade JBLU Now? Get exclusive insights and updates here.